Lusutrombopag
Based on 3 publication(s) in Google Scholar
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.05%
- No. CAS: 1110766-97-6
- Fòrmula: C29H32Cl2N2O5S
- Peso molecular:591.55
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13463
AvatrombopagTPO Receptor Agonist -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-50856
RuxolitinibJAK1/2 Inhibitor -
HY-10218
EverolimusmTORC Inhibitor -
HY-15371
ForskolinAdenylate Cyclase Activator -
HY-10201
SorafenibMultikinase Inhibitor -
HY-17536
SelinexorCRM1 Inhibitor -
HY-13631
ExatecanTopoisomerase I Inhibitor -
HY-15306
EltrombopagTPO Receptor Agonist -
HY-114370
SelpercatinibRET Kinase Inhibitor -
HY-14751
RolapitantNK1 Receptor Antagonist -
HY-10268
BetrixabanFactor Xa Inhibitor
Publications Citing Use of MedChemExpress (MCE) Lusutrombopag
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | CC50 |
14.61 μM
Compound: Lusutrombopag
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
3.78 μM
Compound: Lusutrombopag
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
In Vitro
Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1110766-97-6
-
Appearance Solid
-
Peso molecular 591.55
-
Fòrmula C29H32Cl2N2O5S
-
Color White to off-white
-
SMILES
O=C(O)/C(C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OCCCCCC)C)=C3OC)=CS2)=O)C=C1Cl
-
Synonyms
S-888711
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Thromb Haemost
2022 Aug;20(8):1900-1909. PMID: 35622056 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (84.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.23 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (270 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6905 mL | 8.4524 mL | 16.9047 mL | 42.2619 mL |
| 5 mM | 0.3381 mL | 1.6905 mL | 3.3809 mL | 8.4524 mL | |
| 10 mM | 0.1690 mL | 0.8452 mL | 1.6905 mL | 4.2262 mL | |
| 15 mM | 0.1127 mL | 0.5635 mL | 1.1270 mL | 2.8175 mL | |
| 20 mM | 0.0845 mL | 0.4226 mL | 0.8452 mL | 2.1131 mL | |
| 25 mM | 0.0676 mL | 0.3381 mL | 0.6762 mL | 1.6905 mL | |
| 30 mM | 0.0563 mL | 0.2817 mL | 0.5635 mL | 1.4087 mL | |
| 40 mM | 0.0423 mL | 0.2113 mL | 0.4226 mL | 1.0565 mL | |
| 50 mM | 0.0338 mL | 0.1690 mL | 0.3381 mL | 0.8452 mL | |
| 60 mM | 0.0282 mL | 0.1409 mL | 0.2817 mL | 0.7044 mL | |
| 80 mM | 0.0211 mL | 0.1057 mL | 0.2113 mL | 0.5283 mL |
Lusutrombopag Related Classifications
HY-19883 Related Classifications
Powered by Bioz